Skip to content

Rapid Uptake Products (RUP)

As part of our support to the Accelerated Access Collaborative, AHSNs (through the AHSN Network) are driving adoption of a number of transformative technologies and medicines via the Rapid Uptake Products (RUP) programme.

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.

The 2020/21 programme builds on the successes of the 2019/20 RUPs programme, with themes selected via an open, staged, selection process.

The following innovations will be supported through the Rapid Uptake Products (RUP) Programme for 2020/21:

Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors

The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).

Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath

FeNO (fractional exhaled nitric oxide) is a point of care test to measure type two inflammation in airways, which augments and supports the accuracy of asthma diagnosis. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.

Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma.

Tamoxifen for prevention of breast cancer for women at known risk

NHS England and Improvement, through the Accelerated Access Collaborative (AAC), in collaboration with the AHSN Network and Health Innovation Manchester have launched the drug Tamoxifen as a preventative breast cancer drug, through the Rapid Uptake Products programme.

Tamoxifen is an option for many women who are at high risk of developing breast cancer, for example if they have a significant family history of reproductive cancers.  For women at known risk, Tamoxifen can halve the risk of breast cancer when taken over five years. However, uptake of Tamoxifen is low in clinical practice (roughly 10% in England) due to factors such as access to specialist risk assessment whereby considerations such as family history of reproductive cancers and breast density are reviewed. The aim of this innovation is to improve patient care and outcomes, and ultimately prevent avoidable breast cancer. Read more about Tamoxifen.

Pathway Transformation Fund (PTF) success 

The Pathway Transformation Fund (PTF) is available to help NHS organisations integrate the Rapid Uptake Products into everyday practices. In the first 2021 application round, PTF will support projects to deploy a severe asthma biologics pathway, measuring fractional exhaled nitric oxide (FeNO) concentration in asthma and a lipid management clinical pathway.

PTF applications for the above innovations closed on 30 April 2021 with four applications being successful in the West of England region. Find out more here.

Launch of Tamoxifen PTF application process

The second and final round of 2021 PTF applications will drive the adoption and spread of Tamoxifen. Applications for this product must be submitted by Friday 9 July at 12 noon.

Applications to the PTF should be developed and submitted with the support of your local AHSN RUP lead – our RUP Lead is Clare Evans, Deputy Director of Service and System Transformation – clare.evans14@nhs.net  or Rachel Gibbons, Senior Project Manager – rachel.gibbons10@nhs.net. Please contact Clare or Rachel to discuss your application and to receive an application form, FAQs and Tamoxifen guidance notes.

Three Rapid Uptake Products from the 2019/20 programme will continue through 2020/21:

  • Placental growth factor (PIGF) based tests to help rule out pre-eclampsia quickly so that pregnant women receive the most appropriate care
  • HeartFlow FFRCT – analysis which creates a 3D model of the coronary arteries to help clinicians to rapidly diagnose patients with suspected coronary artery disease from coronary CT angiography
  • PCSK9 inhibitors – will continue as part of a wider Lipid Management workstream. PCSK9 inhibitors are for the treatment of very high cholesterol, and are used together with a statin-type cholesterol-lowering medicine, or for patients who are unable to take or tolerate a statin.

MedTech Funding Mandate

The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate policy, which is delivered in partnership with AHSNs.

The technologies that will be supported by the policy in 2021/22 are:

  1. placental growth factor based testing – a blood test to rule out pre-eclampsia in pregnant women
  2. SecurAcath – for securing percutaneous catheters
  3. HeartFlow – creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages
  4. gammaCore – a handheld device which alleviates the symptoms of severe cluster headaches.

Find out more about the MedTech Funding Mandate here.